课题基金 / 基金详情

ORAL BCX 34 IN T CELL MALIGANCIES

ORAL BCX 34 IN T CELL MALIGANCIES
T 细胞恶性肿瘤中口服 BCX 34
批准号：
6112812
负责人：
MANSOOR N SALEH
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6112812
关键词：
B lymphocyte T lymphocyte blood cell count cell death clinical research clinical trial phase I drug screening /evaluation enzyme mechanism human subject human therapy evaluation pharmacokinetics purine nucleoside phosphorylase

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
BCX-34 is an experimental drug developed by BioCryst Pharmaceuticals Inc., and is being evaluated for use in the treatment of T-cell mediated disases. It has been tested extensively in animals to show that it is safe. Oral BCX-34 has been tested on 3 patients in an initial study to evaluate its safety. During the administration of a single oral dose and a 5 day oral course, no drug related adverse events were noted. This will be the first long term study investigating the effects of this drug in humans. The purpose of this trial is to determine the most effective and least toxic dose of medication needed for a therapeutic response. This will be measured by evaluating levels of drug in the blood and urine, monitoring blood counts for potential abnormalities and assessing the response of the skin and other organs to therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金